In the last 18 months, seven companies and four executives in the generic pharmaceuticals manufacturing sector were charged with antitrust violations, amassing penalties of over $426m. And this month, the Department of Justice Antitrust Division brought its first ever criminal charges for a conspiracy to lower wages to workers against the former owner of a physical therapist staffing company. With enforcement efforts ramping up – and COVID-19 adding additional scrutiny – health care companies will need a comprehensive antitrust compliance program to avoid enforcement actions.

Teva’s market overhang and legal uncertainty intensifies with DOJ charges it conspired to fix generic drug prices. Five other companies have pled guilty and reached deferred prosecution agreements.

Teva’s market overhang and legal uncertainty intensifies with DOJ charges it conspired to fix generic drug prices. Five other companies have pled guilty and reached deferred prosecution agreements.

Complaint names 26 generic dermatologic drug manufacturers and 10 individual executives as defendants, alleging they engaged in a widespread conspiracy to artificially inflate and manipulate prices. State attorneys general say that structural and personnel changes at the companies fostered and facilitated collusion.